2023
Urinary Biomarkers and Kidney Injury in VA NEPHRON-D: Phenotyping Acute Kidney Injury in Clinical Trials
Kiernan E, Hu D, Philbrook H, Ix J, Bonventre J, Coca S, Moledina D, Fried L, Shlipak M, Parikh C. Urinary Biomarkers and Kidney Injury in VA NEPHRON-D: Phenotyping Acute Kidney Injury in Clinical Trials. American Journal Of Kidney Diseases 2023, 83: 151-161. PMID: 37726051, PMCID: PMC10841767, DOI: 10.1053/j.ajkd.2023.07.012.Peer-Reviewed Original ResearchAcute kidney injuryKidney injuryClinical trialsSerum creatinineUrinary biomarkersAKI eventsVA NEPHRONCombination armUrine biomarkersDiabetic chronic kidney disease patientsChronic Kidney Disease trialChronic kidney disease patientsAldosterone system blockadeCombination therapy armKidney Disease TrialRAAS inhibitor therapySafety end pointCombination therapy groupKidney disease patientsBiomarkers of injuryAKI incidenceKidney outcomesMonotherapy armRAAS blockadeRAASi therapyThe Role of Vascular Biomarkers in Outcomes of Patients with Kidney Disease
Shi A, Mansour S. The Role of Vascular Biomarkers in Outcomes of Patients with Kidney Disease. Nephron 2023, 147: 778-781. PMID: 37611550, PMCID: PMC10841333, DOI: 10.1159/000533415.Peer-Reviewed Original ResearchConceptsAcute kidney injuryAngpt-2 levelsCardiovascular diseaseVascular biomarkersPoor outcomeChronic kidney disease patientsPoor long-term outcomesGrowth factorKidney transplant recipientsOutcomes of patientsKidney disease progressionKidney disease patientsLong-term outcomesPlacental growth factorVascular endothelial growth factorEndothelial growth factorAKI patientsAKI survivorsCardiac complicationsKidney injuryTransplant recipientsCardiac surgeryHeart failureHospitalized patientsEndothelial damage
2022
Chapter 47 Motivating the patient with kidney disease to nutrition adherence and other healthy lifestyle activities
Quinn N, Sellinger J, Chwastiak L, Finkelstein F, Martino S. Chapter 47 Motivating the patient with kidney disease to nutrition adherence and other healthy lifestyle activities. 2022, 877-891. DOI: 10.1016/b978-0-12-818540-7.00042-2.Peer-Reviewed Original ResearchKidney disease patientsHealth care providersKidney diseaseMotivational interviewingDisease patientsBusy health care providersHealthy lifestyle activitiesEfficacy of MIHealth care settingsNutrition adherenceEvidence-based practiceChronic diseasesLifestyle changesMedical treatmentPatientsLifestyle activitiesApplication of MIDiseaseBehavior changeChapter 47ProvidersImportant strategy
2021
Profibrotic mechanisms of DPP8 and DPP9 highly expressed in the proximal renal tubule epithelial cells
Zhang Y, Li K, Li Y, Zhao W, Wang L, Chen Z, Ma X, Yao T, Wang J, Dong W, Li X, Tian X, Fu R. Profibrotic mechanisms of DPP8 and DPP9 highly expressed in the proximal renal tubule epithelial cells. Pharmacological Research 2021, 169: 105630. PMID: 33932609, DOI: 10.1016/j.phrs.2021.105630.Peer-Reviewed Original ResearchMeSH KeywordsAdamantaneAnimalsBlotting, WesternCase-Control StudiesCell LineDipeptidasesDipeptidesDipeptidyl-Peptidases and Tripeptidyl-PeptidasesEpithelial-Mesenchymal TransitionFibrosisFluorescent Antibody TechniqueHumansKidney Tubules, ProximalMaleMiceMice, Inbred C57BLReal-Time Polymerase Chain ReactionRenal Insufficiency, ChronicConceptsTubulointerstitial fibrosisTubule epithelial cellsCKD patientsUUO miceHK-2 cell modelChronic kidney disease patientsTGF-β1/Smad signalingUnilateral ureteral obstruction animal modelEpithelial cellsKidney disease patientsHealthy control subjectsKidney biopsy specimensProximal tubule epithelial cellsRenal tubule epithelial cellsRenal proximal tubule epithelial cellsHK-2 cellsPotential therapeutic targetRenal inflammationTubulointerstitial injuryRenal functionUUO groupKidney functionProfibrotic mechanismsControl subjectsDisease patients
2020
Transradial Percutaneous Coronary Intervention in Patients With Advanced Chronic Kidney Disease
Yashima F, Inohara T, Numasawa Y, Kuno T, Sawano M, Ueno K, Shimoji K, Noma S, Fukuda K, Kohsaka S. Transradial Percutaneous Coronary Intervention in Patients With Advanced Chronic Kidney Disease. Cardiovascular Revascularization Medicine 2020, 21: 1138-1143. PMID: 32089511, DOI: 10.1016/j.carrev.2020.02.004.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionTransradial interventionTransfemoral interventionAdvanced CKDCKD patientsHemodialysis initiationPCI patientsCoronary interventionPropensity matchingAdvanced chronic kidney diseaseMore procedure-related complicationsChronic kidney disease patientsTransradial percutaneous coronary interventionConsecutive PCI patientsMulticenter Japanese registryAcute kidney injuryChronic kidney diseaseProcedure-related complicationsGlomerular filtration rateKidney disease patientsOutcomes of interestAKI riskKidney injuryClinical outcomesPeriprocedural bleeding
2013
Chapter 46 Motivating the Kidney Disease Patient to Nutrition Adherence and Other Healthy Lifestyle Activities
Martino S, Chwastiak L, Finkelstein F. Chapter 46 Motivating the Kidney Disease Patient to Nutrition Adherence and Other Healthy Lifestyle Activities. 2013, 775-786. DOI: 10.1016/b978-0-12-391934-2.00046-1.Peer-Reviewed Original ResearchKidney disease patientsDisease patientsMotivational interviewingKidney diseaseHealthcare providersHealthy lifestyle activitiesEfficacy of MINutrition adherenceBusy healthcare providersEvidence-based practiceChronic diseasesLifestyle changesMedical treatmentPatientsLifestyle activitiesApplication of MIHealthcare settingsDiseaseBehavior changeProvidersImportant strategy
2012
Linking Drugs to Obscure Illnesses: Lessons from Pure Red Cell Aplasia, Nephrogenic Systemic Fibrosis, and Reye’s Syndrome. A Report From the Southern Network on Adverse Reactions (SONAR)
Bennett CL, Starko KM, Thomsen HS, Cowper S, Sartor O, Macdougall IC, Qureshi ZP, Bookstaver PB, Miller AD, Norris LB, Xirasagar S, Trenery A, Lopez I, Kahn A, Murday A, Luminari S, Cournoyer D, Locatelli F, Ray P, Mattison DR. Linking Drugs to Obscure Illnesses: Lessons from Pure Red Cell Aplasia, Nephrogenic Systemic Fibrosis, and Reye’s Syndrome. A Report From the Southern Network on Adverse Reactions (SONAR). Journal Of General Internal Medicine 2012, 27: 1697-1703. PMID: 22692632, PMCID: PMC3509314, DOI: 10.1007/s11606-012-2098-1.ChaptersConceptsPure red cell aplasiaNephrogenic systemic fibrosisChronic kidney disease patientsSerious adverse drug reactionsKidney disease patientsRed cell aplasiaReye's syndromeNSF casesCell aplasiaDisease patientsSystemic fibrosisAdministration of aspirinDanish Medicines AgencyAdverse drug reactionsYears of identificationCKD patientsCounter medicationsDrug reactionsAdverse reactionsGadodiamide administrationObscure illnessPediatric useMedicines AgencyPatientsSyndrome
2004
Deficiency of polycystin‐2 reduces Ca2+ channel activity and cell proliferation in ADPKD lymphoblastoid cells
Aguiari G, Banzi M, Gessi S, Cai Y, Zeggio E, Manzati E, Piva R, Lambertini E, Ferrari L, Peters DJ, Lanza F, Harris PC, Borea PA, Somlo S, del Senno L. Deficiency of polycystin‐2 reduces Ca2+ channel activity and cell proliferation in ADPKD lymphoblastoid cells. The FASEB Journal 2004, 18: 884-886. PMID: 15001556, DOI: 10.1096/fj.03-0687fje.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SubstitutionB-LymphocytesCalciumCalcium SignalingCell DivisionCell Line, TransformedCodon, NonsenseEndoplasmic ReticulumGentamicinsHumansIon TransportKidneyMembrane ProteinsMutation, MissenseOrgan SpecificityPlatelet Activating FactorPoint MutationPolycystic Kidney, Autosomal DominantProteinsRNA, MessengerSuppression, GeneticTRPP Cation ChannelsConceptsPlatelet-activating factorAutosomal dominant polycystic kidney disease patientsPolycystic kidney disease patientsKidney disease patientsCell proliferationPolycystin-2B lymphoblastoid cellsDisease patientsADPKD patientsB-LCLIntracellular Ca2PKD2 mutationsPC2 levelsKidney epitheliumPatientsChannel activityLymphoblastoid cellsAminoglycoside antibioticsKidney cellsImportant regulatorHEK293 cellsPKD2 geneFunction activityCa2PKD genes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply